Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07199270
Recruiting Phase 1

A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult

NCT07199270 · tracked via the Priya Life Science China tracker
Sponsor
Genrix (Shanghai) Biopharmaceutical Co., Ltd
Phase
Phase 1
Started
2025-09-18
Last updated
2025-09-30

Condition(s) studied

Health Adult Subjects

Investigational drug(s) / intervention(s)

GR2303 injectionPlaceboGR2303 injectionPlacebo

GR2303 injection: single dose

Placebo: single dose

GR2303 injection: multiple dose

Placebo: multiple dose

Study summary

he goal this clinical trail is to evaluate the safety、Pharmacokinetic and immunogenicity of GR2303 injection。 Subjects will be enrolled in different groups in sequential order, and within each group will be randomly assigned to receive either GR2303 injection or placebo administration, with each Subjects will be enrolled in only one of these groups

Eligibility

Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Healthy adult subjects 2. Signed informed consent Exclusion Criteria: 1. History or presence of any clinically significant organ system disease that could interfere with the objectives of the study or the safety of the subjects. 2. Prior use of drug targeting TNF-like cytokine 1A 3. history of malignant tumor 4. psitive results for Hepatitis B surface antigen (HBsAg), anti Hepatitis C antibody (HCV Ab) or human immunodeficiency virus (HIV)

Primary outcome measure(s)

  • Adverse events — 16 weeks

Trial sites (1)

FacilityCityRegionStatus
Beijing Friendship hospital, Capital Medical University Beijing Beijing Municipality Recruiting

More Genrix (Shanghai) Biopharmaceutical Co., Ltd. trials in China

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma Recruiting
Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE Active, not recruiting
A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma Starting soon
GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma Active, not recruiting
A Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China. Starting soon

Other trials for the same condition

A Phase I Study of HXN5003 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis Starting soon
Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 Compared With EU-Phesgo® Starting soon
An Early-stage Clinical Trial to Evaluate the Safety, Absorption, and Disposition of YR001 Ointment Following Topical Application on the Skin of Healthy Chinese Subjects Recruiting
Effects of NR Supplementation on Metabolic Flexibility in Zone 2 Training Recruiting
Study of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07199270 on ClinicalTrials.gov ↗ ← All trials in China